Recent Updates
Recently added Catalysts
QDEL Positive Sentiment

QuidelOrtho conclut un accord d'approvisionnement stratégique pour élargir son portefeuille mondial d'immunoessais QuidelOrtho a conclu un accord d'approvisionnement stratégique à long terme avec Lifotronic Technology Co, Ltd. (Lifotronic Technology Co., Ltd.,...

Monday, February 16, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: QuidelOrtho has entered into a long-term strategic supply agreement with Lifotronic Technology Co., Ltd. This partnership aims to expand QuidelOrtho's global immunoassay portfolio and enhance customer access to scalable, high-quality, and cost-effective solutions in international markets outside the United States.
Price reaction · baseline $23.58 (2026-02-13 close) · 2 other QDEL headline(s) in the window, move may be shared
day 0 close · peak
-1.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Strategic long-term supply agreement enhances product offerings.
  • Collaboration with Lifotronic expands access to innovative solutions.
  • Focus on high-quality, cost-effective immunoassays for international markets.

Full Press Release Details

L'accord ajoute de nouvelles plateformes d'analyse et élargit la gamme des essais sur les principaux marchés internationaux
SAN DIEGO , 16 février 2026 /PRNewswire/ -- QuidelOrtho a conclu un accord d'approvisionnement stratégique à long terme avec Lifotronic Technology Co, Ltd. (Lifotronic Technology Co., Ltd., code boursier : 688389), afin d'élargir le portefeuille mondial d'immunoessais de QuidelOrtho et d'accélérer l'accès des clients à des solutions évolutives, de haute qualité et rentables sur certains marchés en dehors des États-Unis.

Frequently Asked Questions

What is the purpose of the QuidelOrtho and Lifotronic agreement?

The agreement aims to expand QuidelOrtho's global immunoassay portfolio and improve customer access to innovative solutions.

When was the agreement between QuidelOrtho and Lifotronic announced?

The agreement was announced on February 16, 2026.

What benefits does the agreement provide to QuidelOrtho?

It enhances product offerings and provides access to scalable, high-quality, cost-effective solutions.

Which markets will benefit from this strategic agreement?

The agreement focuses on expanding access to international markets outside the United States.

ShareAdd on Google
Tags: QDEL Viatris Investor Conferences Healthcare QuidelOrtho Lifotronic immunoassays strategic agreement global expansion
Last updated: Feb 16, 2026

Biotech snapshot

Cash runway
$123M liquidity · $7M/mo burn
~17 mo
Low dilution risk